Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity <i>In Vitro</i>.
Rebouissou, Sandra; La Bella, Tiziana; Rekik, Samia; Imbeaud, Sandrine; Calatayud, Anna-Line; Rohr-Udilova, Nataliya; Martin, Yoann; Couchy, Gabrielle; Bioulac-Sage, Paulette; Grasl-Kraupp, Bettina; de Koning, Leanne; Ganne-Carrié, Nathalie; Nault, Jean-Charles; Ziol, Marianne; Zucman-Rossi, Jessica.
Clin Cancer Res
; 23(15): 4364-4375, 2017 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-28246274
Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors.
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.
MiRNA-206 inhibits hepatocellular carcinoma cell proliferation and migration but promotes apoptosis by modulating cMET expression.
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.
Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.
In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.